Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises on the sale of Rg19 to Qlosr Group
Mandate

Vinge advises on the sale of Rg19 to Qlosr Group

November 26, 2021 M&A

Vinge has advised the shareholders of Rg19 in conjunction with the sale of the shares in the company to Qlosr Group, which is listed on NGM Nordic SME. Rg19 is active in business critical IT operations/application operations with a turnover of approximately SEK 100 billion.

Vinge’s team primarily consisted of Johan Winnerblad, Gustav Persson and Viktoria Owetz Leyva.

Related

Vinge advised Precise Biometrics

 Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

 Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026